Hostname: page-component-89b8bd64d-4ws75 Total loading time: 0 Render date: 2026-05-09T23:59:46.137Z Has data issue: false hasContentIssue false

OnabotulinumtoxinA Improves Quality of Life in Chronic Migraine: The PREDICT Study – CORRIGENDUM

Published online by Cambridge University Press:  18 December 2023

Guy Boudreau
Affiliation:
Centre Hospitalier Universitaire de Montréal (CHUM), Montréal, Quebec, Canada
Ian Finkelstein
Affiliation:
Toronto Headache & Pain Clinic, Toronto, Ontario, Canada
Corrie Graboski
Affiliation:
Island Health, Brentwood Bay, British Columbia, Canada
May Ong
Affiliation:
St Paul Hospital, Vancouver, British Columbia, Canada
Suzanne Christie
Affiliation:
University of Ottawa (Neurology), Ottawa, Ontario, Canada
Katherine Sommer
Affiliation:
AbbVie Inc., Marlow, Buckinghamshire, UK
Meetu Bhogal
Affiliation:
AbbVie Inc., Markham, Ontario, Canada
Goran Davidovic
Affiliation:
AbbVie Inc., Markham, Ontario, Canada
Werner J. Becker
Affiliation:
Department of Clinical Sciences, University of Calgary, Calgary, Alberta, Canada
Rights & Permissions [Opens in a new window]

Abstract

Information

Type
Corrigendum
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2023. Published by Cambridge University Press on behalf of Canadian Neurological Sciences Federation